Ana Jovanović

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Dominique P. Germain, Derralynn Hughes, Daniel G. Bichet et al. · New England Journal of Medicine · 2016 · 556 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Derralynn Hughes, Suma P. Shankar, Gere Sunder–Plassmann et al. · Journal of Medical Genetics · 2016 · 386 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry

Alberto Ortíz, Ademola K. Abiose, Daniel G. Bichet et al. · Journal of Medical Genetics · 2016 · 147 citations · Full text

Veterinary Medicine, Clinical Sciences, Pharmacotherapy +10

Phenotypic characteristics of the p.Asn215Ser (p.N215S) <i>G<scp>LA</scp></i> mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study

Dominique P. Germain, Eva Brand, Alessandro P. Burlina et al. · Molecular Genetics & Genomic Medicine · 2018 · 110 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

The Second-Meal Phenomenon in Type 2 Diabetes

Ana Jovanović, Jean Gerrard, Roy Taylor · Diabetes Care · 2009 · 105 citations · Full text

Medicine, Endocrinology, Nutritional Sciences +13